EOFlow announced today that it plans to invest $7.7 billion (9.9 billion Korean Won) in its wholly-owned Pharmeo subsidiary. The investment aims to advance R&D and commercialization of non-insulin drugs with EOFlow’s wearable drug delivery system. Get the full story at our sister site, Drug Delivery Business News.
Pharmaceutical
FDA committee unanimously votes in favor of over-the-counter Narcan from Emergent BioSolutions
Emergent BioSolutions (NYSE:EBS) announced today that its over-the-counter Narcan (naloxone HCl) nasal spray received unanimous approval from governing bodies. The vote came from the FDA Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. A total of 19 voters decided in favor of the benefit-risk profile for Narcan. The voters support […]
Lantheus acquires Cerveau and its imaging agent for Alzheimer’s
Lantheus (Nasdaq:LNTH) announced that it acquired Cerveau Technologies, a developer of a positron emission tomography imaging agent for detecting Alzheimer’s disease. Cerveau develops the MK-6240 second-generation F 18-labeled PET imaging agent. It targets Tau tangles in Alzheimer’s disease. Bedford, Massachusetts–based Lantheus intends to pay an upfront payment and potential development and commercial milestone payments. It […]
Phillips-Medisize unveils new disposable injector pen
Phillips-Medisize, a Molex company, announced today that it expanded its product portfolio with a new disposable pen injector. Hudson, Wisconsin-based Phillips-Medisize designed the new injector for high-volume manufacturing. It intends to offer pharmaceutical companies a familiar, competitive pen injector for faster, more efficient and cost-effective market entry. The company plans to display the pen at […]
Aptar Pharma launches metal-free nasal spray pump
Aptar Pharma announced today that it launched its first metal-free, multidose nasal spray pump, called the APF Futurity. Crystal Lake, Illinois-based Aptar developed APF Futurity to deliver nasal saline and other comparable over-the-counter (OTC) formulations. The company designed the pump specifically for recyclability. Get the full story at our sister site, Drug Delivery Business News.
Biopharma company Chiesi appoints former Medtronic exec as CEO
Chiesi announced today that it appointed former Baxter and Medtronic executive Giuseppe Accogli as its new group CEO. Parma, Italy-based Chiesi said Accogli’s appointment becomes effective April 3, 2023. The R&D-focused pharmaceutical company develops and commercializes products for the hospital, rare disease and adjacent specialty care settings. Accogli brings 25 years of international experience to […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility
Eli Lilly (NYSE:LLY) announced today that it plans to invest an additional $450 million at a North Carolina manufacturing facility. Lilly expects the investment to create at least 100 new jobs at the Research Triangle Park, North Carolina, plant. Its expansion includes additional parenteral filling, device assembly and packaging capacity. Indianapolis-based Lilly said this expansion […]
Eitan Medical opens new manufacturing facility for wearable drug delivery platform
Eitan Medical announced today that it opened a new manufacturing facility at its headquarters to support drug delivery device production. Netanya, Israel-based Eitan intends for the facility to manufacture its Sorrel wearable drug delivery platform. That includes multiple device configurations, such as vial- and cartridge-based wearable injectors. On-site manufacturing supports Eitan’s production scale for its […]
Report: EU may hit Illumina with maximum penalty over Grail deal
Reuters reported this week that Illumina (Nasdaq:ILMN) may face a heavy penalty in Europe for completing its acquisition of Grail. According to the report, the likelihood is that Illumina is penalized with a fine totaling 10% of its global annual turnover — the maximum penalty available. This comes as a result of the company closing […]
Vaxxas raises $23M for needle-free drug delivery tech
Vaxxas announced today that it completed a financing round that brings in $23 million (A$34 million) in new funds. Existing investors OneVentures and UniQuest led the round. New investors, including members of the company’s board and management team, along with individual investors, participated. The company earmarked proceeds to advance its clinical programs, including its needle-free […]